Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
2011-03-01
2011-03-01
Chemyshev, Olga N (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C530S300000, C514S001100, C514S007600, C514S021400
Reexamination Certificate
active
07897723
ABSTRACT:
The invention relates to new peptide compounds capable of modulating cell proliferation, differentiation, survival and/or motility. The peptide compounds of the invention comprise short peptide fragments of the ErbB receptor and are capable of binding to ErbB and modulating activity of the receptor. The invention also relates to antibodies capable of binding to an epitope comprising a peptide sequence of the invention, pharmaceutical compositions comprising the peptide sequences and/or antibodies and uses thereof for treatment of conditions wherein modulating activity of ErbB is needed.
REFERENCES:
patent: 1479693 (2004-11-01), None
patent: WO 01/08636 (2001-02-01), None
patent: WO 2006/026569 (2006-03-01), None
Baselga J, Arteage CL (2005): Critical update and emerging trends in epidermal growth factor receptor targeting in cancer, J Clin Oncol 23 (11), 2445-59.
Bouyan S et al. (2005): The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand, PNAS, vol. 102, No. 42, 15024-15029.
Brandt R et al. (2000): Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 19, 2129-37.
Burgess AW et al. (2003): An open-and-shut case? Recent insight into the activation of EGF/ErbB receptors. Molecular Cell, vol. 12, 541-552.
Cho HS et al. (2002): Structure of the extracellular region of HER3 reveals an interdomain tether. Science, 297, 1330-1333.
Cho HS et al. (2003): Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, vol. 421, 756-760.
Citri A et al. (2003): The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Experimental Cell Research, 284, 54-65.
Di Fiore PP et al. (1987a): ErbB2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, vol. 237, 178-182.
Di Fiore PP et al. (1987b): Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH/3T3 cells. Cell, vol. 51, 1063-1070.
Dmytriyev A et al. (2006): An automatic procedure for evaluation of single cell motility, Cytometry Part A , 69A, 979-985.
Ferguson K et al. (2003): EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerisation. Molecular Cell, vol. 11, 507-517.
Franklin MC et al. (2004): Insights into ErbB signaling from the structure of the ErbB-pertuzumab complex. Cancer Cell, vol. 5, 317-328.
Garrett T et al. (2002): Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alfa. Cell, vol. 110, 763-773.
Garrett TP et al. (2003): The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors, Molecular Cell, vol. 11, 495-505.
Graus-Porta D et al. (1997): ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO Journal, vol. 16, No. 7, 1647-1655.
Guy PM et al. (1994): Insect Cell-Expressed p180erbB3 Possesses an Impaired Tyrosine Kinase Activity. PNAS USA. vol. 91, 8132-8136.
Jorissen R et al. (2003): Epidermal growth factor receptor: mechanisms of activation and signaling. Experimental Cell Research, 284, 31-53.
Krane IM, Leder P (1996): NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12, 1781-8.
Kwok TT, and Sutherland R M (1991): Differences in EGF related radiosensitistion of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer, 64, 251-254.
Marmor MD et al. (2004): Signal transduction andoncogenesis by ErbB/HER receptors. Int J Radiation Oncology, vol. 58, No. 3, 903-913.
Mattoon D et al. (2004): The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. PNAS, vol. 101, 923-928.
Nakamura T, Takasugi H, Aizawa T, Yoshida M, Mizugushi M, Mori Y, Shinoda H, Hayakawa Y, Kawano K (2005): Peptide mimics of epidermal growth factor with antagonistic activity. Journal of Biotechnology, 116, 211-219.
Normanno N. et al. (2003): Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocrine-Related Cancer, 10, 1-21.
Normanno N. et al. (2005): The ErbB receptors and their ligands in cancer: an overview. Current Drug Targets, 6, 243-257.
Ogiso H et al. (2002): Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains, Cell, vol. 110, 775-787.
Olayioye MA et al. (2000): The ErbB signalling network: receptor heterodimerzation in development and cancer. EMBO Journal, vol. 19, 3159-3167.
Pero SC et al. (2004): Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int J Cancer, 111, 951-60.
Schlessinger J (2002): Ligand-induced, receptor-mediated dimerisation and activation of EGF receptor. Cell, vol. 110, 669-672.
Shankar V et al. (1989): Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor alpha cDNA, Mol Carcinogi 2, 1-11.
Tzahar E et al. (1996): A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor
euregulin and epidermal growth factor. Molecular and Cellular Biology, vol. 16, No. 10, 5276-5287.
Worthylake R et al. (1999): ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. Journal of Biological Chemistry, vol. 274, No. 13, 8865-8874.
Xue C et al. (2006): ErbB3-depemdemt motility and intravasation in breast cancer metastasis. Cancer Res, 66 (3) 1418-26.
Yarden Y, Slwkowski M (2001): Untangling the ErbB signalling network. Nature Reviews, vol. 2, 127-137.
Berezin Vladimir
Bock Elisabeth
Povlsen Gro Klitgaard
Chemyshev Olga N
Københavns Universitet
Weingarten Schurgin, Gagnebin & Lebovici LLP
LandOfFree
ErbB receptor-derived peptide fragments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ErbB receptor-derived peptide fragments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ErbB receptor-derived peptide fragments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2710599